Safety and Efficacy Study of SAR 1118 to Treat Dry Eye (OPUS-1)
This study has been completed.
Sponsor:
SARcode Bioscience
Information provided by (Responsible Party):
SARcode Bioscience
ClinicalTrials.gov Identifier:
NCT01421498
First received: August 17, 2011
Last updated: May 28, 2012
Last verified: May 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of the study is to evaluate the efficacy of SAR 1118 Ophthalmic Solution (5.0%) compared to placebo in the treatment of Dry Eye. The safety and tolerability of SAR 1118 Ophthalmic Solution (5.0%) compared to placebo in subjects with dry eye when administered BID for 12 weeks will also be evaluated.
| Condition | Intervention | Phase |
|---|---|---|
|
Dry Eye Keratoconjunctivitis Sicca |
Drug: SAR 1118 |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | A Phase 3, Multicenter, Randomized, Double- Masked and Placebo-Controlled Study Evaluating the Efficacy of a 5.0% Concentration of SAR 1118 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye (OPUS-1) |
Resource links provided by NLM:
Further study details as provided by SARcode Bioscience:
Primary Outcome Measures:
- Inferior Corneal Fluorescein Staining [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
- Visual-related function subscale of OSDI [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
- Safety and tolerability of SAR 1118 Ophthalmic Solution (5.0%) compared to placebo, including incidence and severity of ocular and non-ocular adverse events. [ Time Frame: Week 12 ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- Schirmer Tear Test [ Time Frame: Week 2, 12 ] [ Designated as safety issue: No ]
- Total Corneal Staining [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
- OSDI Score [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
- Ocular Discomfort Score [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
| Enrollment: | 588 |
| Study Start Date: | August 2011 |
| Study Completion Date: | May 2012 |
| Primary Completion Date: | May 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: 5.0% SAR 1118 |
Drug: SAR 1118
Dosage Form: Ophthalmic Solution Dosage: placebo, 5.0% Frequency: BID Duration: 12 weeks
|
| Placebo Comparator: Placebo |
Drug: SAR 1118
Dosage Form: Ophthalmic Solution Dosage: placebo, 5.0% Frequency: BID Duration: 12 weeks
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Willing and able to read, sign, and date the informed consent and HIPAA documents
- Willing and able to comply with all study procedures
- Be at least 18 years of age
- Patient-reported history of dry eye in both eyes
- Demonstrate a positive response when exposed to the Controlled Adverse Environment model
- A negative urine pregnancy test if female of childbearing potential and must use adequate birth control throughout the study period
Exclusion Criteria:
- Any ocular condition that, in the opinion of the Investigator, could affect study parameters including, but not limited to, active ocular infection, ocular inflammation, glaucoma, and/or diabetic retinopathy
- Unwilling to avoid wearing contact lenses for 7 days prior to and for duration of the study period
- Any blood donation or significant loss of blood within 56 days of Visit 1
- Any history of immunodeficiency disorder, positive HIV, hepatitis B, C, or evidence of acute active hepatitis A (anti-HAV IgM), or organ or bone marrow transplant.
- Use of any topical ophthalmic preparations (including artificial tear substitutes) 72 hrs prior to Visit 1 and during the study
- Any significant chronic illness that could interfere with study parameters
- History of laser‑assisted in situ keratomileusis (LASIK) or similar type of corneal refractive surgery within 12 months prior to Visit 1, and/or any other ocular surgical procedure within 12 months prior to Visit 1; or any scheduled ocular surgical procedure during the study period.
- Known history of alcohol and/or drug abuse
- Subjects with Dry eye secondary to scarring or destruction of conjunctival goblet cells (as with Vitamin A deficiency)
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01421498
Locations
| United States, Connecticut | |
| OPUS-1 Investigational Site | |
| Waterbury, Connecticut, United States, 06708 | |
| United States, Kentucky | |
| OPUS-1 Investigational Site | |
| Louisville, Kentucky, United States, 40405 | |
| United States, Maine | |
| OPUS-1 Investigational Site | |
| Augusta, Maine, United States, 04330 | |
| OPUS-1 Investigational Site | |
| Lewiston, Maine, United States, 04243 | |
| United States, Massachusetts | |
| OPUS-1 Investigational Site | |
| Andover, Massachusetts, United States, 01840 | |
| OPUS-1 Investigational Site | |
| Lancaster, Massachusetts, United States, 01523 | |
| OPUS-1 Investigational Site | |
| Quincy, Massachusetts, United States, 02169 | |
| OPUS-1 Investigational Site | |
| Wakefield, Massachusetts, United States, 01880 | |
| OPUS-1 Investigational Site | |
| Winchester, Massachusetts, United States, 01890 | |
| United States, New Hampshire | |
| OPUS-1 Investigational Site | |
| Derry, New Hampshire, United States, 03038 | |
| OPUS-1 Investigational Site | |
| Manchester, New Hampshire, United States, 03101 | |
| United States, Tennessee | |
| OPUS-1 Investigational Site | |
| Memphis, Tennessee, United States, 38119 | |
| United States, Virginia | |
| OPUS-1 Investigational Site | |
| Norfolk, Virginia, United States, 23502 | |
Sponsors and Collaborators
SARcode Bioscience
Investigators
| Study Director: | Charles Semba, MD | SARcode Bioscience, Inc. |
More Information
No publications provided
| Responsible Party: | SARcode Bioscience |
| ClinicalTrials.gov Identifier: | NCT01421498 History of Changes |
| Other Study ID Numbers: | 1118-KCS-200 |
| Study First Received: | August 17, 2011 |
| Last Updated: | May 28, 2012 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by SARcode Bioscience:
|
Dry Eye ophthalmic delivery |
Additional relevant MeSH terms:
|
Keratoconjunctivitis Sicca Dry Eye Syndromes Keratoconjunctivitis Conjunctivitis Conjunctival Diseases |
Eye Diseases Keratitis Corneal Diseases Lacrimal Apparatus Diseases |
ClinicalTrials.gov processed this record on June 18, 2013